Invesco Ltd. Has $122.90 Million Stock Holdings in Vericel Co. (NASDAQ:VCEL)

Invesco Ltd. decreased its position in Vericel Co. (NASDAQ:VCEL - Free Report) by 5.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,238,149 shares of the biotechnology company's stock after selling 130,080 shares during the quarter. Invesco Ltd. owned approximately 4.53% of Vericel worth $122,897,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the business. Congress Asset Management Co. grew its stake in Vericel by 12.6% during the fourth quarter. Congress Asset Management Co. now owns 1,454,139 shares of the biotechnology company's stock valued at $79,847,000 after acquiring an additional 162,419 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Vericel by 119.3% during the fourth quarter. Wellington Management Group LLP now owns 1,288,921 shares of the biotechnology company's stock valued at $70,775,000 after acquiring an additional 701,064 shares during the last quarter. GW&K Investment Management LLC boosted its holdings in Vericel by 2.4% in the fourth quarter. GW&K Investment Management LLC now owns 1,273,964 shares of the biotechnology company's stock valued at $69,953,000 after acquiring an additional 30,180 shares in the last quarter. William Blair Investment Management LLC raised its position in shares of Vericel by 66.3% in the 4th quarter. William Blair Investment Management LLC now owns 1,258,416 shares of the biotechnology company's stock worth $69,100,000 after acquiring an additional 501,736 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Vericel by 1.0% during the 4th quarter. Geode Capital Management LLC now owns 1,166,115 shares of the biotechnology company's stock valued at $64,046,000 after acquiring an additional 12,062 shares during the period.

Remove Ads

Insiders Place Their Bets

In related news, CEO Dominick Colangelo sold 24,850 shares of the business's stock in a transaction that occurred on Thursday, April 10th. The shares were sold at an average price of $41.89, for a total value of $1,040,966.50. Following the completion of the transaction, the chief executive officer now owns 260,354 shares in the company, valued at $10,906,229.06. The trade was a 8.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Robert L. Md Zerbe sold 2,500 shares of the firm's stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total value of $156,250.00. Following the transaction, the director now owns 26,595 shares in the company, valued at approximately $1,662,187.50. This trade represents a 8.59 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 58,942 shares of company stock worth $2,724,548. Insiders own 5.20% of the company's stock.

Vericel Trading Up 1.9 %

Shares of VCEL traded up $0.78 during midday trading on Tuesday, reaching $42.01. 437,192 shares of the company were exchanged, compared to its average volume of 390,908. Vericel Co. has a 1-year low of $37.76 and a 1-year high of $63.00. The company has a market cap of $2.11 billion, a price-to-earnings ratio of 700.28 and a beta of 1.61. The stock has a 50-day moving average price of $48.45 and a 200-day moving average price of $51.39.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on VCEL shares. Stephens reaffirmed an "overweight" rating and set a $65.00 price target on shares of Vericel in a report on Wednesday, January 15th. StockNews.com raised shares of Vericel from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Canaccord Genuity Group lifted their price target on shares of Vericel from $64.00 to $67.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Truist Financial dropped their price objective on Vericel from $61.00 to $51.00 and set a "buy" rating on the stock in a research note on Friday. Finally, HC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of Vericel in a research note on Friday, February 28th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, Vericel presently has an average rating of "Moderate Buy" and a consensus target price of $60.86.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.